A novel subcutaneous infusion delivery system based on osmotic pump: in vitro and in vivo evaluation

Drug Deliv. 2014 Feb;21(1):1-7. doi: 10.3109/10717544.2013.838718. Epub 2013 Oct 9.

Abstract

An economical, convenient portable drug delivery system combining osmotic pump with subcutaneous infusion was developed, which was composed of three primary components: water chamber, osmotic pump chamber and support base. Ceftriaxone sodium (CRO) was selected as the model drug and osmotic pump tablets were prepared. The influence of osmotic agents on drug release profiles was evaluated. As the adjustment made by the osmotic agents was limited, the compositions of semipermeable membrane were investigated to determine significant associations of factors based on orthogonal design. The in vitro release profiles of the optimum formulation achieved to the predetermined value (15 ± 3 min for the initial release time T(i) and 5.75 ± 0.25 h for the extent release time T(e)). The pharmacokinetic profiles of this drug delivery system were evaluated in Beagle dogs. In vivo results demonstrated that the osmotic pump subcutaneous infusion administration was equivalent to intravenous injection administration in terms of bioavailability. Moreover, constant drug plasma levels with minimized fluctuations could be achieved with this osmotic pump subcutaneous infusion system, compared with intravenous injection.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics
  • Biological Availability
  • Ceftriaxone / administration & dosage*
  • Ceftriaxone / pharmacokinetics
  • Dogs
  • Drug Compounding
  • Drug Delivery Systems*
  • Infusions, Subcutaneous
  • Injections, Intravenous
  • Male
  • Osmosis
  • Tablets
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Tablets
  • Ceftriaxone